Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)

Press Releases

We are keeping you informed! If you have questions regarding our press releases, feel free to contact us via the website´s contact form. Stay up-to-date with our companies latest news:

Eckert & Ziegler BEBIG supports parents of children with retinoblastoma in Poland

Seneffe, Belgium, October 31, 2016, Eckert & Ziegler BEBIG took the opportunity to support a group of Polish parents whose children suffer from retinoblastoma - a form of cancer that develops in the retina, the light-detecting tissue of the eye. It is the most common malignant cancer of the eye in children, and it is almost exclusively found in young children.

The dedicated parents sought to acquire a Ru-106 Eye Applicator for the Memorial Health Institute in Warsaw to treat the disease using ophthalmic brachytherapy. Brachytherapy is a form of radiotherapy in which a radioactive plaque containing ruthenium-106 or iodine-125 is sutured to the wall of the eye, adjacent to the tumor, and left in place for several days until the required dose of radiation has been delivered.

Due to a lack of public funding, the group of Polish parents took matters into their own hands. Monika Biernat, the spokeswoman for the group adds: "Obviously, it appears that neither the hospital nor the government have the budget to buy a Ru-106 Eye Applicator and that is why we decided to collect money ourselves to buy the applicator for the hospital, for the children. We would like to thank Eckert & Ziegler BEBIG for their contribution."

The fundraising was initially carried out with the help of the "Kawalek Nieba" ("A Piece of Heaven") foundation, an NGO which aims to help children in need. However, the required amount had not been achieved, so Eckert & Ziegler BEBIG decided to offer a major discount to enable the purchase of the Ru-106 Eye Applicator. Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG, explains: "Mrs. Biernat approached us and explained the situation. We did not hesitate to help children that are urgently awaiting treatment, especially since we strongly believe in ophthalmic brachytherapy."

The Ru-106 Eye Applicator has already arrived in Poland and was used for the first time to treat a patient at the Children's Memorial Health Institute in Warsaw last week.

About Ophthalmic Brachytherapy
The treatment of ocular tumors is selected according to the size and location of the lesion. Whenever possible, attempts are made to preserve the eye and vision. In many centers, brachytherapy is the first choice of treatment for uveal melanomas. This method is also useful for treating certain retinoblastomas and conjunctival melanomas.

Eckert & Ziegler BEBIG offers a series of reliable products for temporary brachytherapy of eye cancers. The company is the only global provider of Ru-106 (Ruthenium-106) Eye Applicators used to treat ocular melanoma and retinoblastoma. For over 30 years, ophthalmologists have favored Ru-106 Eye Applicators due to their superior design and technical features. Owing to the long half-life of Ru-106, the applicators can be used multiple times during a one-year period. With their slim design, they are particularly suitable for treating children.

Eckert & Ziegler BEBIG's ophthalmic product portfolio also includes COMS Eye Applicators, used together with IsoSeed® I-125.

About Kawalek Nieba
Kawalek Nieba was established in order to assist treatment, in order to save the lives and health of sick and disabled children and to help children suffering from malnutrition, poverty and other difficult life situations. The foundation helps children by buying medication, financing medical treatment and life-saving operations, rehabilitation and medical equipment. Kawalek Nieba does not have paid employees but operates on a voluntary basis. All administrative costs associated with maintaining the foundation and other activities are covered through donations.

For more information, please see

About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.

Eckert & Ziegler BEBIG employs approximately 130 people. The company has been listed on the Euronext stock exchange since April 1997.

Annica Witt
Marketing Communication Manager